Related Experiment Video
Updated: Feb 24, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Pharmacologic Management for Heart Failure and Emerging Therapies
Diana H Kim1,2, Feng-Ju Chien3, Howard J Eisen4
1Drexel University College of Medicine, 2900 W Queen Lane, Philadelphia, PA, 19129, USA. dhk45@drexel.edu.
Purpose Of Review:
This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics.
Recent Findings:
HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others. These drugs need to continue to be investigated for safety and efficacy. We predict ivabradine and combinatorial treatment with sacubitril-valsartan to develop as a widespread therapy. New therapies should be aimed at treating HFpEF or target the cardiomyocyte itself.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care
Heart Failure VII: Nursing Interventions
Heart Failure Drugs: β-Blockers

